Rutnin S, et al. - Researchers evaluated oral tranexamic acid (TA) for its efficacy and safety in postinflammatory hyperpigmentation (PIH) prevention and clearance in patients with solar lentigines treated with Q-switched (QS) 532-nm Nd:YAG laser. In this randomized controlled trial, 40 patients with SL treated with QS 532-nm Nd:YAG laser, were randomized to receive oral TA 1,500 mg daily or placebo for 6 weeks. Using digital photographs, dermatoscopy, colorimetry, physician grading scores, and patient satisfaction scores at baseline, 2nd, 4th, 6th, and 12th weeks, blinded investigators evaluated the results. Outcomes suggest the inefficacy of oral TA therapy starting at the first day postlaser treatment for PIH prevention after QS 532-nm Nd:YAG laser in SL. However, oral TA led to significant improvement in PIH clearance by 6th and 12th week, as assessed dermatoscopically.